Exclusive: Novo Nordisk allies itself with one of the buzziest groups in biotech, launching a multi-pronged attack at discovering new drugs
Novo Nordisk established its R&D rep around its in-house expertise that ultimately birthed the GLP-1 blockbuster semaglutide and pushed it to major-market franchise status. But its top execs have been crystal clear that the path to the future of R&D — moving past semaglutide on to the next big thing — points to more external alliances, marrying its global research arms in and out of Copenhagen with outside groups sparking headlines around their discovery work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.